Symbols

ANIK

Anika Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 0

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ANIK

Anika Therapeutics, Inc.

A global joint preservation company focused on early intervention orthopedics

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

11/25/1997

Exchange

NASDAQ Stock Exchange

Full-time Employees

235

Fiscal Year Ends

12-31

Website

www.anika.com

Security Type

Common stock

Office address

32 Wiggins Avenue, Bedford, Massachusetts 01730

Business

Introduction

Anika Therapeutics, Inc., was founded in 1992. The company is a global leader in osteoarthritis pain management and regeneration solutions, focusing on early orthopedic interventions. The Company utilizes its proprietary hyaluronic acid (" HA ") technology to develop differentiated products. Driven by strong partnerships with physicians, Anika is committed to pioneering innovative HA-based technologies that redefine orthopedic care.

Company Financials

EPS

ANIK has released its 2025 Q4 earnings. EPS was reported at 0.31, versus the expected -0.14, beating expectations. The chart below visualizes how ANIK has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ANIK has released its 2025 Q4 earnings report, with revenue of 30.61M, reflecting a YoY change of 0.04%, and net profit of 292.00K, showing a YoY change of 101.34%. The Sankey diagram below clearly presents ANIK's revenue sources and cost distribution.